Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Hyperoxaluria
Interventions
DRUG

ACEI / Angiotensin converting enzyme inhibitor

Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.

DRUG

ARB /Angiotensin Receptor Blocker

Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.

DRUG

Placebo

Patients will receive placebo for 24 months

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER